Expert Review of Neurotherapeutics is an esteemed journal published by Taylor & Francis Ltd, focusing on the rapidly evolving field of neurotherapeutics. With an ISSN of 1473-7175 and an E-ISSN of 1744-8360, this publication aims to bridge the gap between clinical and preclinical research, providing a platform for innovative therapeutic strategies in neurology and neuroscience. The journal boasts impressive impact factor rankings, categorized as Q2 in both clinical neurology and miscellaneous neuroscience, and Q1 in medical pharmacology for 2023. Its reputable placement in Scopus rankings, including Rank #82/400 in clinical neurology, underscores its significance within the medical research community. Spanning from 2001 to 2024, the journal publishes critical reviews and original research articles aimed at enhancing understanding and treatment in neurological disorders. Although it currently does not offer open access, articles published in the journal are crucial for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in neurotherapeutics. With its strong emphasis on rigorous peer-reviewed content, Expert Review of Neurotherapeutics continues to be a vital resource for those dedicated to improving patient outcomes in the realm of neurology.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

EXPERT OPINION ON PHARMACOTHERAPY, published by Taylor & Francis Ltd, stands as a vital resource in the fields of medicine and pharmacology, consistently recognized for its significant contributions to both disciplines. With an impressive impact factor, this journal ranks in the second quartile (Q2) across several key categories, including Medicine (miscellaneous), Pharmacology, and Medical Pharmacology, underscoring its influence within the academic community. Since its inception in 1999, the journal has provided a platform for peer-reviewed articles that critically evaluate emerging therapies and innovative pharmacological approaches, making it essential reading for researchers, healthcare professionals, and students alike. Although it operates under a subscription model, its comprehensive coverage of pharmacotherapeutic developments ensures that it remains a cornerstone for those seeking new insights and expert analyses in the rapidly evolving landscape of drug therapy.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

Pain and Therapy is a prestigious, peer-reviewed journal published by SPRINGER INTERNATIONAL PUBLISHING AG that has been a beacon of research in the field of pain management and neurology since its inception in 2012. With an ISSN of 2193-8237 and an E-ISSN of 2193-651X, this open access journal facilitates the dissemination of high-quality research to a global audience. Recognized within the top Q1 quartile for Anesthesiology and Pain Medicine, and the Q2 category for Clinical Neurology, it ranks impressively within the Scopus indexing, positioned at #20/136 in its primary category, demonstrating an 85th percentile standing. The journal's commitment to open access enhances its impact, allowing researchers, clinicians, and students to explore and contribute to critical developments in pain therapy and management. The convergence of cutting-edge research and innovative therapeutic strategies makes Pain and Therapy an essential resource for anyone dedicated to advancing knowledge in this vital field.

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.